NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · BIAF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
bioAffinity Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
bioAffinity Technologies, Inc.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of -$31.50. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow bioAffinity Technologies, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:03 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | -$4.800.0% vs estimate | $1.85M-12.11% vs estimate |
|---|
| Q4 2024 | Mar 31, 2025 | -$6.31-50.24% vs estimate | $2.20M-8.93% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -$4.80-6.67% vs estimate | $2.35M-7.43% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$2.31-$0.02 (-0.86%)
Artelo Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.71% below the high.
$5.60+$0.09 (+1.63%)
GT Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.52% below the high.
$0.84+$0.19 (+29.23%)
Salarius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.41% below the high.
$1.10-$0.05 (-4.35%)
WORK Medical Technology Group Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 100.0% below the high.
$3.75+$0.03 (+0.81%)
Revelation Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.76% below the high.
$0.65-$0.01 (-1.18%)
Protagenic Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.77% below the high.
